TITLE

SUBERGEN'S DECITABINE GRANTED 'ORPHAN DRUG' STATUS IN EUROPE

PUB. DATE
April 2003
SOURCE
Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on an 'Orphan Medicinal Product' designation granted for the anticancer drug Decitabine of SuperGen Inc. by the European Agency for the Evaluation of Medicinal Products, as of April 2003.
ACCESSION #
9427661

 

Related Articles

  • Orphan drugs.  // Applied Clinical Trials;Nov2002, Vol. 11 Issue 11, p14 

    Reports that the U.S. Food and Drug Administration has granted orphan drug designation to Decitabine developed by Dublin, California-based SuperGen Inc. for the treatment of sickle-cell anemia.

  • Products.  // Pharmaceutical Executive;Nov98, Vol. 18 Issue 11, p114 

    Provides information on new products from the pharmaceutical industry announced or launched in 1998. Details on the marketing clearance received by Rhone-Poulenc Rorer for Estalis; Approval of the RFS 2000 of SuperGen; Indications of Seroxat/Paxil from SmithKline Beecham.

  • SuperGen and GSK partner in cancer drug development.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p15 

    The article presents information on the collaboration between companies, SuperGen Inc. and GlaxoSmithKline (GSK), for developing cancer drug. The collaboration is to discover and develop cancer therapeutics based on epigenetic targets. As per the deal SuperGen will receive 3 million dollars...

  • Uncertainty surrounds SuperGen's Dacogen study.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p9 

    Focuses on the completion of a randomized phase III study of Dacogen for injection as treatment for myelodysplastic syndromes initiated by SuperGen Inc. Characterization of myelodysplastic syndromes; Impact of the drug with disease progression to leukemia; Method used to analyze the data.

  • SuperGen happy with FDA meeting regarding Orathecin application.  // PharmaWatch: Biotechnology;October 2003, Vol. 2 Issue 10, p11 

    Reports on the meeting between SuperGen Inc. with the U.S. Food and Drug Administration (FDA) regarding the drug company's clinical package to complete its new drug application for Orathecin capsules. Intention of SuperGen to complete its ongoing data verification activities as per FDA...

  • INDUSTRY UPDATE - Other Cancers.  // PharmaWatch: Cancer;May 2003, Vol. 2 Issue 5, p13 

    Reports developments related to cancer from March 2003 to April 2003. Approval of the Emend drug of Merck & Co. Inc.; Criticism of the U.S. Food and Drug Administration on the cancer drug of SuperGen Inc.; Commencement of the phase II trial of cancer vaccine by Antigenics Inc.

  • AACR-NCI-EORTC Conference.  // BioWorld Today;10/26/2007, Vol. 18 Issue 209, p6 

    The article presents an update on the multitargeted tyrosine kinase inhibitor being developed by SuperGen Inc. of Dublin, California. At the American Association for Cancer Research, National Cancer Institute and European Organization for Research and Treatment of Cancer conference in San...

  • SuperGen presents positive data on Nipent in NHL.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p14 

    Reports that two studies of SuperGen Inc.'s drug Nipent, as part of combination therapy, is active in patients with low-grade B-cell non-Hodgkin's lymphoma. Approval of Nipent as a single-agent treatment for patients with hairy cell leukemia; Doses; Adverse events; Toxicity events.

  • INDUSTRY UPDATE - Key Announcements.  // PharmaWatch: Cancer;May 2003, Vol. 2 Issue 5, p2 

    Reports developments related to cancer from March 2003 to April 2003. Commencement of the phase III clinical trial for treatment of metastatic colorectal cancer of Schering AG; Expansion of the GVAV lung cancer vaccine trial of Cell Genesys Inc.; Criticism of the U.S. Food and Drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics